<DOC>
	<DOC>NCT00945958</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.</brief_summary>
	<brief_title>Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description>This is a multicenter, open label, non-randomized, single-arm, extension safety study to evaluate the long-term safety of SPARC0913. Subjects who completed the prior evaluator-masked clinical non-inferiority Study participated in the current study.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Men and women aged â‰¥18 years Willing to participate and giving written informed consent Willing to commit to study medicationdosing, study visits and followup visits to complete evaluation Eligible to receive Latanoprost once a daily as monotherapy for treatment of glaucoma History of allergic hypersensitivity or poor tolerance to latanoprost History of Substance abuse or addiction (alcohol drugs) in the past 3 years History of chronic use of concomitant medications in neurologic or psychiatric illness that would affect assessment of safety and effectiveness of the study medication Any abnormality preventing IOP measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>